Page last updated: 2024-10-19

inositol and Parkinsonian Disorders

inositol has been researched along with Parkinsonian Disorders in 3 studies

Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"Gaucher disease is an autosomal recessive disease, caused by a lack or functional deficiency of the lysosomal enzyme, glucocerebrosidase (GCase)."1.42Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease. ( Alvarez-Fischer, D; Andreas, H; Hirsch, EC; Höglinger, GU; Höllerhage, M; Lu, L; Noelker, C; Oertel, WH; Roscher, R; Sturn, A; Vulinovic, F, 2015)
"Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations."1.32Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism. ( Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's2 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mus, L1
Siani, F1
Giuliano, C1
Ghezzi, C1
Cerri, S1
Blandini, F1
Noelker, C1
Lu, L1
Höllerhage, M1
Vulinovic, F1
Sturn, A1
Roscher, R1
Höglinger, GU1
Hirsch, EC1
Oertel, WH1
Alvarez-Fischer, D1
Andreas, H1
Podell, M1
Hadjiconstantinou, M1
Smith, MA1
Neff, NH1

Other Studies

3 other studies available for inositol and Parkinsonian Disorders

ArticleYear
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity.
    Neurobiology of disease, 2019, Volume: 124

    Topics: Animals; Disease Models, Animal; Enzyme Inhibitors; Glucosylceramidase; Inositol; Male; Mice; Mice,

2019
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease.
    Journal of the neurological sciences, 2015, Sep-15, Volume: 356, Issue:1-2

    Topics: 1-Deoxynojirimycin; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cell Count; Cells,

2015
Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
    Experimental neurology, 2003, Volume: 179, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aspartic Acid; Brain; Cats; Choline; Corpus S

2003